Akiko et al. developed monoclonal antibodies known as CRE-DR against dog IgE, which have been validated through enzyme-linked immunosorbent assay (ELISA) for their specific reactivity to human IgE, indicating the potential of these monoclonal antibodies in treating allergies [98]. This evidence concerns the gene IGHE and allergic disease.